Daniel J. Breslin

Array ( [id] => 17929845 [patent_doc_number] => 20220324970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION [patent_app_type] => utility [patent_app_number] => 17/630718 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -140 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830161 [patent_doc_number] => 20220267465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => BINDING MEMBERS [patent_app_type] => utility [patent_app_number] => 17/631002 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20645857 [patent_doc_number] => 12600793 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Chimeric antigen receptors with MAGE-A4 specificity and uses thereof [patent_app_type] => utility [patent_app_number] => 17/629562 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 27721 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792481 [patent_doc_number] => 20220251572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => IMMUNE CELLS DEFECTIVE FOR SUV39H1 [patent_app_type] => utility [patent_app_number] => 17/629256 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18374378 [patent_doc_number] => 20230149457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => LONG LIVED T CELLS FOR TREATING HIV INFECTION [patent_app_type] => utility [patent_app_number] => 17/627947 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948398 [patent_doc_number] => 12319745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Antibodies having specificity for CD38 and uses thereof [patent_app_type] => utility [patent_app_number] => 17/627674 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17197 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108279 [patent_doc_number] => 12358987 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof [patent_app_type] => utility [patent_app_number] => 17/624031 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 4493 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 243 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020649 [patent_doc_number] => 20220372148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => A PHARMACEUTICAL COMPOSITION FOR TREATING HEMATOLOGICAL CANCER [patent_app_type] => utility [patent_app_number] => 17/624502 [patent_app_country] => US [patent_app_date] => 2020-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343140 [patent_doc_number] => 12466862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Plant-produced mABs against chikungunya virus with enhanced effector function and efficacy [patent_app_type] => utility [patent_app_number] => 17/615803 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 12865 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16299059 [patent_doc_number] => 20200284782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => Test method for toxicity of raw dinotefuran drug on early life stage of fish [patent_app_type] => utility [patent_app_number] => 16/810514 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 885 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398229 [patent_doc_number] => 20220040319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHODS OF TREATING OCULAR CANCER USING ANTI-MET ANTIBODIES AND BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET [patent_app_type] => utility [patent_app_number] => 16/796380 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492663 [patent_doc_number] => 12534526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => NKG2A antibody, preparation method therefor and application thereof [patent_app_type] => utility [patent_app_number] => 17/292379 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 31 [patent_no_of_words] => 20874 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 243 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511558 [patent_doc_number] => 20200390815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/970930 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555778 [patent_doc_number] => 20210000926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 16/968792 [patent_app_country] => US [patent_app_date] => 2019-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389923 [patent_doc_number] => 20230158141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => Conjugates of Biomolecule and Use Thereof [patent_app_type] => utility [patent_app_number] => 16/761477 [patent_app_country] => US [patent_app_date] => 2018-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761477 [rel_patent_id] =>[rel_patent_doc_number] =>)